The Inimmune team is passionate about developing disease-modifying immunotherapies for indications with major unmet medical needs. Two of our assets, INI-4001 (a TLR7/8 agonist) and INI-2004 (a TLR4 agonist) have advanced into clinical trials. INI-4001 has demonstrated safety, tolerability and on-target immune activation in a Phase 1 clinical trial for all solid tumors. Our dedicated team has also advanced INI-2004, a next generation TLR4 agonist, into the clinic via intranasal administration, where it demonstrated an exemplary safety profile. We are now developing sublingual formulations for clinical use in food allergy therapy. Our adjuvants are in late-stage development, with clinical trials currently being initiated for an INI-4001 adjuvanted opioid vaccine and additional adjuvanted vaccine clinical trials planned for 2027. At the discovery and pre-clinical stage, Inimmune has a deep pipeline of innate agonists and antagonists that are being developed as disease-modifying immunotherapies for other inflammatory diseases.
Inimmune is a clinical-stage, fast-moving innovative biotech company focused on the discovery and development of novel immunotherapeutics to treat inflammatory conditions. Inimmune has a deep pipeline of innate immune modulating clinical and pre-clinical assets to treat inflammatory diseases, such as cancer, food allergy, and autoimmune conditions, and for use as vaccine adjuvants. Anchoring these seemingly disparate disease indications is the innate immune system, where all immune responses begin. Altering the immune response from the first step creates a deep ripple effect, driving sustained and durable change to treat and prevent disease.
The Inimmune team is passionate about developing disease-modifying immunotherapies for indications with major unmet medical needs. Two of our assets, INI-4001 (a TLR7/8 agonist) and INI-2004 (a TLR4 agonist) have advanced into clinical trials. INI-4001 has demonstrated safety, tolerability and on-target immune activation in a Phase 1 clinical trial for all solid tumors. Our dedicated team has also advanced INI-2004, a next generation TLR4 agonist, into the clinic via intranasal administration, where it demonstrated an exemplary safety profile. We are now developing sublingual formulations for clinical use in food allergy therapy. Our adjuvants are in late-stage development, with clinical trials currently being initiated for an INI-4001 adjuvanted opioid vaccine and additional adjuvanted vaccine clinical trials planned for 2027. At the discovery and pre-clinical stage, Inimmune has a deep pipeline of innate agonists and antagonists that are being developed as disease-modifying immunotherapies for other inflammatory diseases.
Inimmune will complete a Phase I clinical trial in oncology using INI-4001, a TLR7/8 agonist, in Q4 of 2026. INI-4001 monotherapy has demonstrated safety, tolerability and on-target immune activation in a Phase 1 clinical trial for all solid tumors. We are currently seeking partners to advance INI-4001 to the next stage of clinical development as a combination immunotherapy.
INI-2004 has also successfully completed clinical trials in allergy when used as an intranasal therapy, demonstrating an exemplary safety profile. Inimmune is currently developing sublingual formulations for use in food allergy therapy and preparing for clinical trials that use intranasal INI-2004 as a mucosal adjuvant for respiratory pathogen vaccines.
We partner with some of the best universities and biotech companies. Want to co-create and develop novel immunotherapeutics to improve human health?
We are a biotech company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics. We have extensive expertise in synthetic and process chemistry, drug formulation, immunology, and clinical translation. Our goal at Inimmune is to recruit, hire, and maintain a diverse workforce. Equal employment opportunity is good business. Equal opportunity applies to all aspects of our employment, including recruitment, selection, hiring, training, transfer, promotion, termination, compensation, and benefits.
